Regorafenib combined with immunotherapy versus regorafenib as second-line therapy in patients with advanced hepatocellular carcinoma: A multicenter real-world study

被引：1
|
作者：
Li, B-K. [1 ]
Yuan, Y. [1 ]
Qiao, L. [1 ]
He, W. [1 ]
Wang, G. [2 ]
Chen, H. [3 ]
Zhang, B. [4 ]
Fuxi, H. [5 ]
Qiu, J. [1 ]
机构：
[1] Sun Yat Sen Univ, Dept Liver Surg, Canc Ctr, Guangzhou, Peoples R China
[2] Guangzhou Med Univ, Dept Hepatobiliary Surg, Affiliated Hosp 1, Guangzhou, Peoples R China
[3] First Peoples Hosp Foshan, Dept Hepat Surg, Foshan, Peoples R China
[4] Guangzhou Panyu Dist He Xian Mem Hosp, Dept Oncol, Guangzhou, Peoples R China
[5] Panyu Cent Hosp, Canc Inst Panyu, Dept Oncol, Guangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2095
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
949P
引用
收藏
页码：S596 / S596
页数：1
相关论文
共 50 条
  • [41] Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison
    Santoni, Matteo
    Aurilio, Gaetano
    Massari, Francesco
    Grande, Enrique
    Matrana, Marc R.
    Rizzo, Mimma
    De Giorgi, Ugo
    Incorvaia, Lorena
    Martignetti, Angelo
    Molina-Cerrillo, Javier
    Zabalza, Ignacio Ortego
    Mollica, Veronica
    Rizzo, Alessandro
    Battelli, Nicola
    Porta, Camillo
    CLINICAL GENITOURINARY CANCER, 2022, 20 (03) : 285 - 295
  • [42] COST-EFFECTIVENESS ANALYSIS OF REGORAFENIB AS A SECOND-LINE THERAPY IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA IN CHINA
    Xiao, D.
    Zhu, S.
    Sun, W.
    Xuan, J.
    VALUE IN HEALTH, 2019, 22 : S187 - S188
  • [43] Efficacy and safety of TACE combined with ablation and regorafenib for unresectable hepatocellular carcinoma: A real-world study.
    Xiong, Yiqi
    Gao, WenFeng
    Long, Jiang
    Hu, CaiXia
    Yuan, ChunWang
    Sun, Yu
    Shi, QinSheng
    Sun, Bin
    Zhang, YingHua
    Cui, XiongWei
    Hao, MeiJun
    Li, Jianjun
    Zhang, Yonghong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [44] Tailoring second-line or above therapy for patients with advanced or metastatic gastric cancer: A multicenter real-world study
    Nie, Caiyun
    Xu, Weifeng
    Lv, Huifang
    Gao, Xiaohui
    Li, Guofeng
    Chen, Beibei
    Wang, Jianzheng
    Liu, Yingjun
    Zhao, Jing
    He, Yunduan
    Wang, Saiqi
    Chen, Xiaobing
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [45] Efficacy and safety of regorafenib in combination with immune checkpoint inhibitor therapy as second-line and third-line regimen for patients with advanced hepatocellular carcinoma: a retrospective study
    Zhao, Jie
    Guo, Yongzhong
    Feng, Tianshuo
    Rong, Dawei
    Kong, Xiangyi
    Huang, Tian
    Lopez-Lopez, Victor
    Yarmohammadi, Hooman
    Sakamoto, Yoshihiro
    Zhu, Deming
    Yao, Aihua
    Xia, Yongxiang
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2023, 14 (06) : 2549 - 2558
  • [46] Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey
    Hacioglu, Muhammet Bekir
    Kostek, Osman
    Karabulut, Senem
    Tastekin, Didem
    Goksu, Sema Sezgin
    Alandag, Celal
    Akagunduz, Baran
    Bilgetekin, Irem
    Caner, Burcu
    Sahin, Ahmet Bilgehan
    Yildiz, Birol
    Kose, Fatih
    Kaplan, Muhammet Ali
    Gulmez, Ahmet
    Dogan, Ender
    Guven, Deniz Can
    Gurbuz, Mustafa
    Ergun, Yakup
    Karaagac, Mustafa
    Demiray, Atike Gokcen
    Turker, Sema
    Sakalar, Teoman
    Ozkul, Ozlem
    Telli, Tugba Akin
    Sahin, Suleyman
    Kilickap, Saadettin
    Bilici, Ahmet
    Erdogan, Bulent
    Cicin, Irfan
    JOURNAL OF BUON, 2020, 25 (04): : 1897 - 1903
  • [47] Comparison of clinical outcome between Nivolumab and Regorafenib as second-line systemic therapy after Sorafenib failure in patients with advanced hepatocellular carcinoma
    Lee, Jae Seung
    Lee, Hong Jun
    Lee, Hye Won
    Kim, Beom Kyung
    Kim, Seung Up
    Park, Jun Yong
    Ahn, Sang Hoon
    Kim, Do Young
    JOURNAL OF HEPATOLOGY, 2023, 78 : S595 - S595
  • [48] Efficacy and safety of regorafenib + PD-1 inhibitor combined with local therapy as secondline treatment in patientwith advanced hepatocellular carcinoma: A multicenter retrospective real-world study.
    Fu, Xiaobo
    Mu, Maoyuan
    Qi, Han
    Jiang, Weiwei
    Chen, Zixiong
    Gao, Fei
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [49] Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan
    Sadahisa Ogasawara
    Yoshihiko Ooka
    Norio Itokawa
    Masanori Inoue
    Shinichiro Okabe
    Atsuyoshi Seki
    Yuki Haga
    Masamichi Obu
    Masanori Atsukawa
    Ei Itobayashi
    Hideaki Mizumoto
    Nobuyuki Sugiura
    Ryosaku Azemoto
    Kengo Kanayama
    Hiroaki Kanzaki
    Susumu Maruta
    Takahiro Maeda
    Yuko Kusakabe
    Masayuki Yokoyama
    Kazufumi Kobayashi
    Soichiro Kiyono
    Masato Nakamura
    Tomoko Saito
    Eiichiro Suzuki
    Shingo Nakamoto
    Shin Yasui
    Akinobu Tawada
    Tetsuhiro Chiba
    Makoto Arai
    Tatsuo Kanda
    Hitoshi Maruyama
    Naoya Kato
    Investigational New Drugs, 2020, 38 : 172 - 180
  • [50] Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan
    Ogasawara, Sadahisa
    Ooka, Yoshihiko
    Itokawa, Norio
    Inoue, Masanori
    Okabe, Shinichiro
    Seki, Atsuyoshi
    Haga, Yuki
    Obu, Masamichi
    Atsukawa, Masanori
    Itobayashi, Ei
    Mizumoto, Hideaki
    Sugiura, Nobuyuki
    Azemoto, Ryosaku
    Kanayama, Kengo
    Kanzaki, Hiroaki
    Maruta, Susumu
    Maeda, Takahiro
    Kusakabe, Yuko
    Yokoyama, Masayuki
    Kobayashi, Kazufumi
    Kiyono, Soichiro
    Nakamura, Masato
    Saito, Tomoko
    Suzuki, Eiichiro
    Nakamoto, Shingo
    Yasui, Shin
    Tawada, Akinobu
    Chiba, Tetsuhiro
    Arai, Makoto
    Kanda, Tatsuo
    Maruyama, Hitoshi
    Kato, Naoya
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (01) : 172 - 180
12345